November 30, 2016 - By Clifton Ray · 0 Comments
The stock of Champions Oncology Incorporated (NASDAQ:CSBR) registered an increase of 223.86% in short interest. CSBR’s total short interest was 28,500 shares in November as published by FINRA. Its up 223.86% from 8,800 shares, reported previously. With 56,400 shares average volume, it will take short sellers 1 days to cover their CSBR’s short positions. The short interest to Champions Oncology Incorporated’s float is 0.82%. About 1.82M shares traded hands or 2395.10% up from the average. Champions Oncology Inc (NASDAQ:CSBR) has declined 51.03% since April 27, 2016 and is downtrending. It has underperformed by 56.25% the S&P500.
Champions Oncology, Inc. is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The company has a market cap of $25.58 million. The Firm has two business divisions: Personalized Oncology Solutions and Translational Oncology Solutions (TOS). It currently has negative earnings. The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.
Champions Oncology, Inc., incorporated on June 4, 1985, is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Firm has two business divisions: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The Company’s POS business provides physicians and patients information to help guide the development of personalized treatment plans. The Company’s TOS business provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development. The Company’s TumorGraft Technology Platform consists of processes, physical tumors and information that it uses to personalize the development and use of oncology drugs. Each tumor from individual patients that it has preserved for future implantation in mice, along with the patient data and molecular information associated with these tumors, are referred to as TumorGrafts or Patient Derived XenoGrafts of PDX Models. The collection of TumorGrafts is referred to as the Company’s TumorBank. As of April 30, 2016, the Company has approximately 800 PDX Models in its TumorBank. It implants tumors in mice to provide pharmaceutical and biotechnology companies the opportunity to test oncology compounds on multiple tumors to test efficacy and simulate the results of human clinical trials.
More notable recent Champions Oncology Inc (NASDAQ:CSBR) news were published by: Prnewswire.com which released: “Champions Oncology Signs $2 million Contract” on November 17, 2016, also Prnewswire.com with their article: “Champions Oncology Beats Revenue Guidance for Quarter; Reaffirms Full Year …” published on September 09, 2016, Prnewswire.com published: “Champions Oncology Announces Initiation of Prospective Correlative Trial in …” on January 21, 2016. More interesting news about Champions Oncology Inc (NASDAQ:CSBR) were released by: Prnewswire.com and their article: “Champions Oncology Announces Revenue Up 26%, Projects 43% – 60% Growth For …” published on July 28, 2016 as well as Prnewswire.com‘s news article titled: “Champions Oncology Announces Reverse Stock Split in Preparation for Uplisting …” with publication date: August 12, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Clifton Ray